Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Wilmington, Del., February 24, 2025 -- Hyfe, Inc., the global leader in AI-powered respiratory care, today announces its partnership with KYORIN Pharmaceutical Co. Ltd for the development and commercialization of the world’s first prescription digital therapeutic (DTx) to treat chronic cough in the Japanese market. Built on the proven principles of Behavioral Cough Suppression Therapy (BCST) and powered by Hyfe’s advanced cough monitoring technology, this collaboration marks a significant milestone in leveraging advanced digital therapeutics to address a debilitating condition that affects millions worldwide.
“This is a major step forward in addressing a highly underserved medical condition; by transforming a therapy previously confined to in-person settings, we are dramatically expanding access to millions worldwide who struggle with chronic cough,” said Dr. Peter Small, MD, Chief Medical Officer at Hyfe. “By combining KYORIN’s extensive expertise in respiratory medicine and our powerful AI, the partnership is creating opportunities for deeper patient engagement, more precise treatment understanding, and improved patient outcomes. Together, we’re taking on chronic cough management and revolutionizing respiratory health care.”
Chronic cough affects 10% of adults globally with a significant impact on their quality of life. The condition is often overlooked by traditional healthcare systems, particularly for underserved populations disproportionately affected, including women and older adults. Hyfe's innovative, non-invasive digital therapeutic addresses barriers to cough treatment by leveraging AI that unobtrusively monitors cough patterns with 90%+ accuracy on any mic-enabled device. This enables continuous, real-time tracking and personalized treatment interventions.
BCST, a non-pharmacological treatment method used to reduce chronic cough through cognitive-behavioral strategies, improves cough outcomes in up to 87% of patients. In addition, BCST has been shown to reduce cough in people with refractory chronic cough and unexplained chronic cough by 41%, significantly higher than any drug available on the market. However, BCST is only offered in-person by under 200 speech language pathologists in the U.S. and very few in Japan. Hyfe’s DTx bridges this gap by combining BCST with AI-powered cough monitoring to deliver personalized treatment plans on patients’ own mobile phones, empowering patients and providers to better treat the condition regardless of their geographic location.
The chronic cough market, valued at $17 billion and growing at 6.39% annually, represents a significant opportunity for digital therapeutics to transform care while reducing healthcare costs and improving patient outcomes.
To explore partnership opportunities or learn more about Hyfe’s digital therapeutic platform, visit hyfe.com or schedule a call here.
About Hyfe, Inc.
Hyfe, Inc. is the global leader in AI-powered cough-monitoring technology. The company’s patented machine-learning software enables passive, long-term monitoring of cough frequency, revealing novel health insights. Hyfe delivers cough-monitoring solutions that empower pharma and academic researchers to advance clinical trials, enable healthcare providers to optimize patient care, and power digital therapeutics to transform the management of respiratory illness, including chronic cough. Hyfe’s technology has been used in 50+ research studies, and its long-term partners include global pharma companies and leading academic institutions. More information is available at hyfe.com.
About KYORIN Pharmaceutical Co. Ltd.
KYORIN Pharmaceutical Co., Ltd. was founded in 1923. Accelerating its evaluation and acquisition of in-licensed products and establishing a presence in designated fields, Kyorin aims to contribute broadly to people’s health by pursuing innovation in drug discovery, in order to strengthen drug discovery capability and create high-value new drugs that meet medical needs.
###
Media contact:
_____________________________________
1 Arinze JT, de Roos EW, Karimi L, Verhamme KMC, Stricker BH, Brusselle GG. Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study. ERJ Open Res. 2020 Apr 19;6(2):00300-2019. doi: 10.1183/23120541.00300-2019. PMID: 32337212; PMCID: PMC7167208. https://pmc.ncbi.nlm.nih.gov/articles/PMC7167208/
2 Slovarp, L.J., Jetté, M.E., Gillespie, A.I. et al. Evaluation and Management Outcomes and Burdens in Patients with Refractory Chronic Cough Referred for Behavioral Cough Suppression Therapy. Lung 199, 263–271 (2021). https://doi.org/10.1007/s00408-021-00442-w
3 Chamberlain Mitchell SA, Garrod R, Clark L, Douiri A, Parker SM, Ellis J, Fowler SJ, Ludlow S, Hull JH, Chung KF, Lee KK, Bellas H, Pandyan A, Birring SS. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017 Feb;72(2):129-136. doi: 10.1136/thoraxjnl-2016-208843. Epub 2016 Sep 28. PMID: 27682331. https://pubmed.ncbi.nlm.nih.gov/27682331/
